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Letters to the Editor
p53 and angiogenesis in non-small-cell lung cancer
Sir
The prognostic role of p53 nuclear expression in non-small-cell
lung cancer (NSCLC) remains contradictory. One of the first
papers on early operable cancer failed to confirm an impact ofp53
expression on survival (McLaren et al, 1992). In this study, five
different antibodies were used in frozen material. Although some
studies subsequently showed a positive correlation of mutant p53
expression with worse outcome, an equally high number ofstudies
failed to confirm such an observation (Mitsudomi et al, 1993;
Kashii et al, 1995; Nishio et al, 1996). Surprisingly, several studies
correlated positive p53 expression with better prognosis (Lee et al,
1995; Passlick et al, 1995; Top et al, 1995).
The p53 oncogene has recently been shown to inhibit angio-
genesis through regulation of thrombospondin-1, an inhibitor of
angiogenesis (Dameron et al, 1994). The first clinicopathological
study that examined possible correlation of mutant p53 expression
with angiogenesis was reported by Giatromanolaki et al (1996a), in
which no correlation was found with vascular grade, assessed with
JC70 MAb. JC70 (anti-CD31) is more specific than anti-Factor
VIII antibody endothelial cell marker. In a comparative study, we
observed that 22% of cases with high microvessel score on JC70
had a low score on anti-Factor VIII staining. Anti-CD31 reveals a
2.5 times higher number of microvessels and four times higher
number ofendothelial cells compared with anti-factor VIII staining
(Giatromanolaki et al). Comparing vascular grade with the p53
score obtained by McLaren et al (1992) (five different antibodies),
no correlation was found. In addition, using the results obtained
with PAb248 (Pezzella et al, 1994) recognising the cytoplasmic
wild-type p53 protein, no association was confirmed (F Pezzella).
In a subsequent study on the angiogenic factor thymidine phos-
phorylase (PD-ECGF) expression in non-small-cell lung cancer,
we observed that cancer cell overexpression associated with
increased neoangiogenesis (Koukourakis et al, 1997). Again, p53
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Figure 1 Microvessel score (MS), p53 and c-erbB-2 expression assessed
with JC70, PAbl801 and NCL-CB1 1 antibodies, respectively, in 107 cases of
non-small-cell lung cancer. The mean MS was 63 ± 49 and 55 ±42 for p53-
positive and p53-negative cases respectively (P = 0.35). The mean MS was
63 ±47 and 43 ± 39 for c-erbB-2-positive and c-erbB-2-negative cases
respectively (P= 0.08)
expression was not associated with TP expression. The interesting
recent observation (Fontanini et al, 1997) that p53 nuclear expres-
sion correlates with angiogenesis and survival is not in accordance
with our previously published results. The method of this paper
considered microvessel counting in one focus ofhigh (factor VIII
assessed) vascularization while the mean score of p53-positive
cells was assessed in five fields. It is well known that one angio-
genic hot spot does not always define high vascularization. If loss
of wild-type p53 does suppress thrombospondin-l expression,
increased angiogenesis in the stroma arround p53-stained areas
would be expected. However, what the p53 status was within the
area of high neovascularization or what the angiogenesis was
within the fields of p53 positivity was not studied. The very low
'r-factor' (0.41) reported for linear regression analysis further
suggests that p53 may have a more complicated role. An eventual
angiogenesis regulating role ofp53 or p21 alone or in cooperation
with other oncogenes, such as c-erbB-2 (Giatromanolaki et al,
1996b) demands further investigation (Fig. l).
A Giatromanolaki andMIKoukourakis, SaintNikolas
Histopathology Unit and Dept ofRadiotherapy - Oncology,
University Hospital ofIraklion, Iraklion 71110, PO Box 1352,
Crete, Greece
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p53 and angiogenesis in non-small-cell lung cancer
Reply to the letter from Giatromanolaki and
Koukourakis
Sir
We completely agree with Dr Giatromanolaki about the controver-
sial prognostic role of p53 expression in human cancers and, in
particular, in lung cancer. There are in fact several studies that fail
to evidence any statistical association between p53 alterations and
poor prognosis in NSCLC (McLaren et al, 1992; Kashii et al,
1995; Kwa et al, 1996; Nishio et al, 1996) and others that find an
association between p53 alterations and a favourable behaviour.
However, several other studies, which evaluated both p53 muta-
tions and p53 nuclear overexpression, have underlined a strong
statistical association between p53 alterations and poor prognosis
in this type of cancer (Quinlan et al, 1992; Horio et al, 1993;
Mitsudomi et al, 1993; Fontanini et al, 1995a; Harpole et al, 1995;
Dalquen et al, 1996; Irie et al, 1996; Dosaka-Akita et al, 1997;
Fontanini et al, 1997, Fukuyama et al, 1997), stimulating further
investigation in this field. As regards the discrepancies that arise
between these studies, we have identified some possible causes:
(1) the cohorts ofpatients analysed (prospective or retrospective);
(2) the different stages of the tumours; (3) the histological types
investigated; (4) the methodologies used. We believe that the most
correct analyses tending towards a prognostic evaluation of a
specific factor should use prospective and consecutive series of
patients, because retrospective cohorts more often lead to the
introduction ofpotential biases.
With regard to the evaluation ofthe relationship between angio-
genesis, oncogenes and tumour-suppressor genes, we believe that
in this field also there is a long way to go. In fact, very few studies
have been performed in this respect, and itis too restrictive to draw
final conclusions on the basis of only two investigations, mainly
because these analyses disagree on some points. We are not
completely sure that anti-FVIII antibodies are less specific than
other types of endothelium-related antibodies as the anti-FVIII
antibody has been defined as being the most specific marker for
endothelial cells (Weidner, 1995; Folkman and Weidner, 1996),
although it may be a little less sensitive in non-expert hands.
Moreover, it has been reported by Folkman and Weidner (1996)
that, although apparently more sensitive, CD31 strongly cross-
reacts with plasma cells (DeYoung et al, 1993; Longacre et al,
1994), and this complication can markedly obscure the micro-
vessels in tumours with a prominent plasmacellular inflammatory
background. Weidner (1995) reports that a valid alternative to
FVIII antibodies may be represented by the anti-CD34 antibody
and, recently, Tomisaki et al (1996) demonstrated a very strong
correlation between FVIII and CD34 immunoreactivity in
colorectal cancer (r = 0.956, P = 0.01). Like antibodies to FVIII,
anti-CD31 and anti-CD34 do not immunostain all intratumoral
microvessels, and it would be useful to dispose of new antibodies
raised against proliferating or activated endothelial cells.
However, we would like to underline that anti-FVIII antibodies
have been used in most of the analyses on vascular count
performed in NSCLC (five out of seven), and a significant associ-
ation between vascular count and poorprognosis has been found in
all of these series (Macchiarini et al, 1992; Yamasaki et al, 1994;
Fontanini et al, 1995b; Angeletti et al, 1996; Giatromanolaki et al,
1996; Harpole et al, 1996).
According to Weidner (1995) and Folkman (1995), we evalu-
ated the vascular count in our tumours in the areas with a greater
number of microvessels ('hot spot') after scanning more than one
section ofthe tumour. The 'hot spot', so defined, is considered as
being representative of tumoral angiogenesis by these authors,
despite the many discussions held in this field so far. In general,
we agree with the concept that tumour cells have different angio-
genic potentials and that the 'hot spot', ifcarefully identified by an
expert pathologist, may provide reliable information on the angio-
genic pattern ofa tumour. From this point ofview, we believe that
the association that we found between p53 and vascular count in
our series ofpatients (Fontanini et al, 1997) should be considered
exciting, although it is not in agreement with the data by
Giatromanolaki et al (1996) - it represents, on the one hand, a
further contribution to the discussion on the relationship between
tumour-suppressor genes and angiogenesis and, on the other hand,
it prompts us to perform further studies as suggested by Dr
Giatromanolaki.
G Fontanini, Department ofOncology, Division ofPathology,
University ofPisa, via Roma 57, 56126 Pisa, Italy
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